Phase II clinical trial - Sein métastatique RH+

XENERA-1 (BI 1280-0022)
Sein métastatique RH+
Ouvert depuis le: 03.23.2019
Site: Paris
Public cible
Adulte
A multi-centre, double-blind, placebo-controlled,randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease
Description de l'essai

The main objective of the trial is to assess the anti-tumor activity of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in post menopausal patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.